Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Switch in Exudative AMD With PED Previously Treated With Ranibizumab
NCT02157077Phase 3Completed
- Sponsor
- Centre Hospitalier Intercommunal de Créteil
- Start
- Dec 2013
- Primary completion
- Dec 2015
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in neovascular age-related macular degeneration (nAMD), sponsored by Centre Hospitalier Intercommunal de Créteil. Started Dec 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (nAMD)
Beyond the preview
Go deeper on NCT02157077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157077.